Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis.
Fiche publication
Date publication
juillet 2023
Journal
Expert review of anticancer therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr JANNIER Sarah
Tous les auteurs :
Lemelle L, Guillemot D, Hermann AL, Gauthier A, Carton M, Corradini N, Rome A, Berlanga P, Jourdain A, Marie Cardine A, Jannier S, Boutroux H, Defachelles AS, Aerts I, Geoerger B, Karanian M, Doz F, Brisse HJ, Schleiermacher G, Delattre O, Pierron G, Orbach D
Lien Pubmed
Résumé
NTRK gene fusions have been identified in various tumors; some requiring aggressive therapy and sometimes new TRK inhibitors (TRKi). We aimed to describe a national, unselected, retrospective, multicenter cohort.
Mots clés
Burden of therapy, Fusion transcript tumor, Infantile fibrosarcoma, Neurotrophic tropomyosin receptor kinase, TRK inhibitor
Référence
Expert Rev Anticancer Ther. 2023 07 11;: